A Phase III study by Genentech has met its co-primary endpoint of overall survival at interim analysis and demonstrated that first-line treatment with the combination of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped patients with advanced non-squamous non-small cell lung cancer live significantly longer compared with Avastin plus carboplatin and paclitaxel.
Furthermore, a survival benefit was observed across key subgroups – including those with varying levels of PD-L1 expression. This data will be submitted to health authorities globally, including the FDA and EMA.
“We are pleased that the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer. These results add to the growing body of evidence supporting the role of combining Tecentriq with Avastin.” commented Sandra Horning (Roche/Genentech).
IMpower150 is one of eight Phase III lung cancer studies underway, evaluating Tecentriq alone or in combination with other medicines. Following the positive IMpower150 and IMpower131 studies, there are a further three Phase III lung cancer studies expected to report this year.